Oliver LANGER GROUP    SITE

  • Front Pharmacol. 2021;12:698966. ABCB1 and ABCG2 together limit the distribution of ABCB1/ABCG2 Substrates to the human retina and the ABCG2 Single Nucleotide Polymorphism Q141K (c.421C> A) may lead to increased drug xxposure. El Biali M, Karch R, Philippe C, Haslacher H, Tournier N, Hacker M, Zeitlinger M, Schmidl D, Langer O, Bauer M. PubMed
  • Pharmaceutics. 2021;13:918. Imaging-based characterization of a Slco2b1(-/-) mouse model using [11C]Erlotinib and [99mTc]Mebrofenin as probe substrates. Marie S, Hernández-Lozano I, Breuil L, Truillet C, Hu S, Sparreboom A, Tournier N, Langer O. PubMed
  • Eur J Pharm Sci. 2021;163:105854. Influence of ABC transporters on the excretion of ciprofloxacin assessed with PET imaging in mice. Hernández-Lozano I, Wanek T, Sauberer M, Filip T, Mairinger S, Stanek J, Traxl A, Karch R, Schuetz JD, Langer O. PubMed
  • Pharm Res. 2021;38:127-140. Influence of Cation Transporters (OCTs and MATEs) on the renal and hepatobiliary disposition of [11C]Metoclopramide in mice. Hernández-Lozano I, Mairinger S, Sauberer M, Stanek J, Filip T, Wanek T, Ciarimboli G, Tournier N, Langer O. PubMed
  • Mol Imaging Biol. 2021;23:180-185. Human biodistribution and radiation dosimetry of the P-Glycoprotein radiotracer [11C]Metoclopramide. Bauer M, Barna S, Blaickner M, Prosenz K, Bamminger K, Pichler V, Tournier N, Hacker M, Zeitlinger M, Karanikas G, Langer O. PubMed.
  • Int J Mol Sci. 2020;21:8245. Brain distribution of dual ABCB1/ABCG2 substrates is unaltered in a Beta-Amyloidosis mouse model. Wanek T, Zoufal V, Brackhan M, Krohn M, Mairinger S, Filip T, Sauberer M, Stanek J, Pekar T, Pahnke J, Langer O. PubMed
  • J Cereb Blood Flow Metab. 2020;In press. Complete inhibition of ABCB1 and ABCG2 at the blood-brain barrier by co-infusion of erlotinib and tariquidar to improve brain delivery of the model ABCB1/ABCG2 substrate [11C]erlotinib. Tournier N, Goutal S, Mairinger S, Hernández-Lozano I, Filip T, Sauberer M, Caillé F, Breuil L, Stanek J, Freeman AF, Novarino G, Truillet C, Wanek T, Langer O. PubMed
  • Clin Pharmacol Ther. 2020;In press. Impaired clearance from the brain increases the brain exposure to metoclopramide in elderly subjects. Bauer M, Bamminger K, Pichler V, Weber M, Binder S, Maier-Salamon A, Tahir A, Jäger W, Haslacher H, Tournier N, Hacker M, Zeitlinger M, Langer O. PubMed
  • Nat Rev Drug Discov. 2020;19:801-818. Phase 0/microdosing approaches: time for mainstream application in drug development? Burt T, Young G, Lee W, Kusuhara H, Langer O, Rowland M, Sugiyama Y. PubMed
  • Pharmaceutics. 2020;12:486. Validation of pharmacological protocols for targeted inhibition of canalicular MRP2 activity in hepatocytes using [99mTc]mebrofenin imaging in rats. Marie S, Hernández-Lozano I, Breuil L, Saba W, Novell A, Gennisson JL, Langer O, Truillet C, Tournier N. PubMed
  • J Nucl Med. 2020;In press. Assessing the activity of Multidrug Resistance-Associated Protein 1 at the lung epithelial barrier. Mairinger S, Sake JA, Hernandez Lozano I, Filip T, Sauberer M, Stanek J, Wanek T, Ehrhardt C, Langer O. PubMed
  • Expert Opin Drug Metab Toxicol. 2020;16:149-164. Use of imaging to assess the activity of hepatic transporters. Hernández Lozano I, Langer O. PubMed
  • EJNMMI Radiopharm Chem. 2019;4:31. Pitfalls and solutions of the fully-automated radiosynthesis of [11C]metoclopramide. Pichler V, Ozenil M, Bamminger K, Vraka C, Hacker M, Langer O, Wadsak W. PubMed
  • EJNMMI Res. 2019;9:110. Assessment of brain delivery of a model ABCB1/ABCG2 substrate in patients with non-contrast-enhancing brain tumors with positron emission tomography. Wulkersdorfer B, Bauer M, Karch R, Stefanits H, Philippe C, Weber M, Czech T, Menet MC, Declèves X, Hainfellner JA, Preusser M, Hacker M, Zeitlinger M, Müller M, Langer O. PubMed
  • J Nucl Med. 2020;61:1050-1057. Imaging P-glycoprotein Induction at the Blood-Brain Barrier of a Beta-Amyloidosis Mouse Model with 11C-Metoclopramide PET. Zoufal V, Mairinger S, Brackhan M, Krohn M, Filip T, Sauberer M, Stanek J, Wanek T, Tournier N, Bauer M, Pahnke J, Langer O. PubMed
  • Mol Pharm. 2020;17:316-326. Measurement of Hepatic ABCB1 and ABCG2 Transport Activity with [11C]Tariquidar and PET in Humans and Mice. Hernández Lozano I, Bauer M, Wulkersdorfer B, Traxl A, Philippe C, Weber M, Häusler S, Stieger B, Jäger W, Mairinger S, Wanek T, Hacker M, Zeitlinger M, Langer O. PubMed
  • Eur J Nucl Med Mol Imaging. 2019;In press. In vivo characterization of [18F]AVT-011 as a radiotracer for PET imaging of multidrug resistance. Kannan P, Füredi A, Dizdarevic S, Wanek T, Mairinger S, Collins J, Falls T, van Dam RM, Maheshwari D, Lee JT7, Szakács G, Langer O. PubMed
  • J Nucl Med. 2020;61:306. Pharmacokinetic imaging with radiolabeled molecularly targeted anticancer drugs. Bauer M, Zeitlinger M, Langer O. PubMed
  • J Cereb Blood Flow Metab. 2019;in press. Measurement of cerebral ABCC1 transport activity in wild-type and APP/PS1-21 mice with positron emission tomography. Zoufal V, Mairinger S, Krohn M, Wanek T, Filip T, Sauberer M, Stanek J, Kuntner C, Pahnke J, Langer O. PubMed
  • Mol Pharmacol. 2019;96:138-147. Generation and characterization of an Abcc1 humanized mouse model (hABCC1flx/flx) with knockout capability. Krohn M, Zoufal V, Mairinger S, Wanek T, Paarmann K, Brüning T, Eiriz I, Brackhan M, Langer O, Pahnke J. PubMed
  • AAPS J. 2019;21:61. Towards improved pharmacokinetic models for the analysis of transporter-mediated hepatic disposition of drug molecules with Positron Emission Tomography. Hernández Lozano I, Karch R, Bauer M, Blaickner M, Matsuda A, Wulkersdorfer B, Hacker M, Zeitlinger M, Langer O. PubMed
  • Clin Pharmacol Ther. 2019;105:1061-1064. Imaging P-Glycoprotein function at the Blood-Brain Barrier as a determinant of the variability in response to Central Nervous System drugs. Bauer M, Tournier N, Langer O. PubMed
  • Transl Psychiatry. 2019;9:80. PET imaging of the mouse brain reveals a dynamic regulation of SERT density in a chronic stress model. Reisinger SN, Wanek T, Langer O, Pollak DD. PubMed
  • J Nucl Med. 2019;60:985-991. Impact of P-glycoprotein function on the brain kinetics of the weak substrate 11C-Metoclopramide assessed with PET imaging in humans. Tournier N, Bauer M, Pichler V, Nics L, Klebermass EM, Bamminger K, Matzneller P, Weber M, Karch R, Caille F, Auvity S, Marie S, Jaeger W, Wadsak W, Hacker M, Zeitlinger M, Langer O. PubMed
  • Theranostics. 2018;8:6210-6232. PET-MR and SPECT-MR multimodality probes: Development and challenges. Yang CT, Ghosh KK, Padmanabhan P, Langer O, Liu J, Eng DNC, Halldin C, Gulyás B. PubMed
  • Nucl Med Biol. 2018;67:21-26. Molar activity - The keystone in 11C-radiochemistry: An explorative study using the gas phase method. Pichler V, Zenz T, Philippe C, Vraka C, Berrotéran-Infante N, Pfaff S, Nics L, Ozenil M, Langer O, Willeit M, Traub-Weidinger T, Lanzenberger R, Mitterhauser M, Hacker M, Wadsak W. PubMed
  • J Cereb Blood Flow Metab. 2018:271678X18806640. Age dependency of cerebral P-glycoprotein function in wild-type and APPPS1 mice measured with PET. Zoufal V, Wanek T, Krohn M, Mairinger S, Filip T, Sauberer M, Stanek J, Pekar T, Bauer M, Pahnke J, Langer O. PubMed
  • Mol Pharm. 2019;16:1282-1293. Inhibition of ABCB1 and ABCG2 at the mouse Blood-Brain Barrier with marketed drugs to improve brain delivery of the model ABCB1/ABCG2 substrate [11C]erlotinib. Traxl A, Mairinger S, Filip T, Sauberer M, Stanek J, Poschner S, Jäger W, Zoufal V, Novarino G, Tournier N, Bauer M, Wanek T, Langer O. PubMed
  • Eur J Microbiol Immunol (Bp). 2018;8:78-86. Humanization of the Blood-Brain Barrier transporter ABCB1 in mice disrupts genomic locus - Lessons from three unsuccessful approaches. Krohn M, Wanek T, Menet MC, Noack A, Declèves X, Langer O, Löscher W, Pahnke J. PubMed
  • Contrast Media Mol Imaging. 2018;2018:2487405. Liver imaging and hepatobiliary contrast media. Pastor CM, Langer O, Van Beers BE. PubMed
  • J Nucl Med. 2018;pii: jnumed.118.216432. A proof-of-concept study to inhibit ABCG2- and ABCB1-mediated efflux transport at the human blood-brain barrier. Bauer M, Karch R, Wulkersdorfer B, Philippe C, Nics L, Klebermass EM, Weber M, Poschner S, Haslacher H, Jäger W, Tournier N, Wadsak W, Hacker M, Zeitlinger M, Langer O. PubMed
  • Mol Pharm. 2018;15:4589-4598. Effect of rifampicin on the distribution of [11C]Erlotinib to the liver: a translational PET study in humans and in mice. Bauer M, Traxl A, Matsuda , Karch R, Philippe C, Nics L, Klebermass EM, Wulkersdorfer B, Weber M, Poschner S, Tournier N, Jäger W, Wadsak W, Hacker M, Wanek T, Zeitlinger M, Langer O. PubMed
  • EJNMMI Res. 2018;8:81. Impact of rifampicin-inhibitable transport on the liver distribution and tissue kinetics of erlotinib assessed with PET imaging in rats. Amor D, Goutal S, Marie S, Caillé F, Bauer M, Langer O, Auvity S, Tournier N. PubMed
  • Mol Imaging Biol. 2018;In press. Influence of multidrug resistance-associated proteins on the excretion of the ABCC1 imaging probe 6-Bromo-7-[11C]Methylpurine in mice. Zoufal V, Mairinger S, Krohn M, Wanek T, Filip T, Sauberer M, Stanek J, Traxl A, Schuetz JD, Kuntner C, Pahnke J, Langer O. PubMed
  • EJNMMI Radiopharm Chem. 2018;3:8. Comparison of fully-automated radiosyntheses of [11C]erlotinib for preclinical and clinical use starting from in target produced [11C]CO2 or [11C]CH4. Philippe C, Mairinger S, Pichler V, Stanek J, Nics L, Mitterhauser M, Hacker M, Wanek T, Langer O, Wadsak W. PubMed
  • Pharmacol Ther. 2018; in press. Imaging techniques to study drug transporter function in vivo. Tournier N, Stieger B, Langer O. PubMed
  • Eur J Drug Metab Pharmacokinet. 2018; in press. Pharmacokinetics of the P-gp inhibitor Tariquidar in rats after intravenous, oral, and intraperitoneal administration. Matzneller P, Kussmann M, Eberl S, Maier-Salamon A, Jäger W, Bauer M, Langer O, Zeitlinger M, Poeppl W. PubMed
  • Eur J Pharm Sci. 2018;115:212-222. Influence of breast cancer resistance protein and P-glycoprotein on tissue distribution and excretion of Ko143 assessed with PET imaging in mice. Mairinger S, Zoufal V, Wanek T, Traxl A, Filip T, Sauberer M, Stanek J, Kuntner C, Pahnke J, Müller M, Langer O. PubMed
  • Drug Deliv Transl Res. 2018;8:536-542. Intravenous infusion for the controlled exposure to the dual ABCB1 and ABCG2 inhibitor elacridar in nonhuman primates. Goutal S, Langer O, Auvity S, Andrieux K, Coulon C, Caillé F, Gervais P, Cisternino S, Declèves X, Tournier N. PubMed
  • Clin Pharmacol Ther. 2018; 104:139-147. Influence of OATPs on hepatic disposition of erlotinib measured with positron emission tomography. Bauer M, Matsuda A, Wulkersdorfer B, Philippe C, Traxl A, Özvegy-Laczka C, Stanek J, Nics L, Klebermass EM, Poschner S, Jäger W, Patik I, Bakos É, Szakács G, Wadsak W, Hacker M, Zeitlinger M, Langer O. PubMed
  • Drug Metab Dispos. 2017;45:1093-1100. Hepatocyte-specific deletion of EGFR in mice reduces hepatic Abcg2 transport activity measured by [11C]erlotinib and Positron Emission Tomography. Traxl A, Komposch K, Glitzner E, Wanek T, Mairinger S, Langer O, Sibilia M. PubMed
  • Front Neurosci. 2017 Jul;11:396. Reproducibility of quantitative brain imaging Using a PET-only and a combined PET/MR system. Lassen ML, Muzik O, Beyer T, Hacker M, Ladefoged CN, Cal-González J, Wadsak W, Rausch I, Langer O, Bauer M. PubMed
  • Nucl Med Biol. 2017;52:7-15. [11C]Erlotinib PET cannot detect acquired erlotinib resistance in NSCLC tumor xenografts in mice. Traxl A, Beikbaghban T, Wanek T, Kryeziu K, Pirker C, Mairinger S, Stanek J, Filip T, Sauberer M, Kuntner C, Berger W, Langer O. PubMed
  • Br J Clin Pharmacol. 2017;83:1991-1999. Effect of P-glycoprotein inhibition at the blood-brain barrier on brain distribution of (R)-[11 C]verapamil in elderly vs. young subjects. Bauer M, Wulkersdorfer B, Karch R, Philippe C, Jäger W, Stanek J, Wadsak W, Hacker M, Zeitlinger M, Langer O. PubMed
  • J Pharm Sci. 2017;106:2780-2786. A prediction method for P-glycoprotein-mediated drug-drug interactions at the human Blood-Brain Barrier from blood concentration-time profiles, validated with PET data. Matsuda A, Karch R, Bauer M, Traxl A, Zeitlinger M, Langer O. PubMed
  • Nucl Med Biol. 2017;44:83-89. On the applicability of [18F]FBPA to predict L-BPA concentration after amino acid preloading in HuH-7 liver tumor model and the implication for liver boron neutron capture therapy. Grunewald C, Sauberer M, Filip T, Wanek T, Stanek J, Mairinger S, Rollet S, Kudejova P, Langer O, Schütz C, Blaickner M, Kuntner C. PubMed
  • J Nucl Med. 2017;58:678-681. Assessment of P-glycoprotein transport activity at the human blood-retina barrier with (R)-11C-verapamil PET. Bauer M, Karch R, Tournier N, Cisternino S, Wadsak W, Hacker M, Marhofer P, Zeitlinger M, Langer O. PubMed
  • Appl Radiat Isot. 2016;118:67-72. Preloading with L-BPA, L-tyrosine and L-DOPA enhances the uptake of [18F]FBPA in human and mouse tumour cell lines Wingelhofer B, Kreis K, Mairinger S, Muchitsch V, Stanek J, Wanek T, Langer O, Kuntner C. PubMed
  • Bioorg Med Chem. 2016;24:5326-5339. Synthesis and preclinical characterization of 1-(6'-deoxy-6'-[18F]fluoro-β-d-allofuranosyl)-2-nitroimidazole (β-6'-[18F]FAZAL) as a positron emission tomography radiotracer to assess tumor hypoxia. Wanek T, Kreis K, Križková P, Schweifer A, Denk C, Stanek J, Mairinger S, Filip T, Sauberer M, Edelhofer P, Traxl A, Muchitsch VE, Mereiter K, Hammerschmidt F, Cass CE, Damaraju VL, Langer O, Kuntner C. PubMed
  • J Nucl Med. 2017;58:117-122. Strategies to inhibit ABCB1- and ABCG2-mediated efflux transport of erlotinib at the blood-brain barrier: a PET study in non-human primates. Tournier N, Goutal S, Auvity S, Traxl A, Mairinger S, Wanek T, Helal OB, Buvat I, Soussan M, Caillé F, Langer O. PubMed
  • J Clin Pharmacol. 2016;56:S143-56. Use of PET imaging to evaluate transporter-mediated drug-drug interactions. Langer O. PubMed
  • J Nucl Med. 2016; Whole-body distribution and radiation dosimetry of 11C-Elacridar and 11C-Tariquidar in humans. Bauer M, Blaickner M, Philippe C, Wadsak W, Hacker M, Zeitlinger M, Langer O. PubMed
  • Mol Pharmacol. 2016;89:492-504. Generation and characterization of a Breast Cancer Resistance Protein humanized mouse model. Dallas S1, Salphati L2, Gomez-Zepeda D1, Wanek T, Chen L, Chu X, Kunta J, Mezler M, Menet MC, Chasseigneaux S, Declèves X, Langer O, Pierre E, DiLoreto K, Hoft C, Laplanche L, Pang J, Pereira T, Andonian C, Simic D, Rode A, Yabut J, Zhang X, Scheer N, PubMed
  • J Pharm Sci. 2016;105:106-12. Influence of 24-Nor-Ursodeoxycholic acid on hepatic disposition of [(18)F]Ciprofloxacin, a Positron Emission Tomography study in mice. Wanek T, Halilbasic E, Visentin M, Mairinger S, Römermann K, Stieger B, Kuntner C, Müller M, Langer O, Trauner M. PubMed
  • J Nucl Med. 2015;56:1930-6. Breast Cancer Resistance Protein and P-Glycoprotein influence in vivo disposition of 11C-Erlotinib. Traxl A, Wanek T, Mairinger S, Stanek J, Filip T, Sauberer M, Müller M, Kuntner C, Langer O. PubMed
  • Mol Pharm. 2015;12:3214-25. Factors governing P-Glycoprotein-mediated drug-drug interactions at the blood-brain barrier measured with Positron Emission Tomography. Wanek T, Römermann K, Mairinger S, Stanek J, Sauberer M, Filip T, Traxl A, Kuntner C, Pahnke J, Bauer F, Erker T, Löscher W, Müller M, Langer O. PubMed
  • J Med Chem. 2015;58:6058-80. Development of Fluorine-18 labeled metabolically activated tracers for imaging of drug efflux transporters with Positron Emission Tomography. Sander K, Galante E, Gendron T, Yiannaki E, Patel N, Kalber TL, Badar A, Robson M, Johnson SP, Bauer F, Mairinger S, Stanek J, Wanek T, Kuntner C, Kottke T, Weizel L, Dickens D, Erlandsson K, Hutton BF, Lythgoe MF, Stark H, Langer O, Koepp M, Årstad E. PubMed
  • Nucl Med Biol. 2015;42:585-9. [(18)F]FDG is not transported by P-glycoprotein and breast cancer resistance protein at the rodent blood-brain barrier. Wanek T, Traxl A, Bankstahl JP, Bankstahl M, Sauberer M, Langer O, Kuntner C. PubMed
  • J Cereb Blood Flow Metab. 2015;35:743-6. Approaching complete inhibition of P-glycoprotein at the human blood-brain barrier: an (R)-[11C]verapamil PET study. Bauer M, Karch R, Zeitlinger M, Philippe C, Römermann K, Stanek J, Maier-Salamon A, Wadsak W, Jäger W, Hacker M, Müller M, Langer O. PubMed
  • Drug Metab Dispos. 2014;42:2007-15. Role of drug transporters in imaging in health and disease. Stieger B, Unadkat JD, Prasad B, Langer O, Gali H. PubMed
  • Clin Pharmacol Ther. 2014;96:206-13. Using positron emission tomography to study transporter-mediated drug-drug interactions in tissues. Wulkersdorfer B, Wanek T, Bauer M, Zeitlinger M, Müller M, Langer O. PubMed
  • Numerous other publications on transporters at the blood-brain barrier in humans and rodents …
  • AAPS J. 2006;8:E263-71. Microdialysis versus other techniques for the clinical assessment of in vivo tissue drug distribution. Brunner M, Langer O. PubMed
  • Antimicrob Agents Chemother. 2004;48:3850-7. [18F]Ciprofloxacin, a new positron emission tomography tracer for noninvasive assessment of the tissue distribution and pharmacokinetics of ciprofloxacin in humans. Brunner M, Langer O, Dobrozemsky G, Müller U, Zeitlinger M, Mitterhauser M, Wadsak W, Dudczak R, Kletter K, Müller M. PubMed

PubMed

Vienna, Austria

LANGER OLIVER.jpg

Last update: August 2021